Equities Analysts Set Expectations for ADIL Q1 Earnings

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Investment analysts at Litchfield Hills Research upped their Q1 2025 earnings per share (EPS) estimates for Adial Pharmaceuticals in a report issued on Tuesday, March 18th. Litchfield Hills Research analyst T. O’neill now anticipates that the company will earn ($0.37) per share for the quarter, up from their prior forecast of ($0.40). The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q2 2025 earnings at ($0.28) EPS, Q3 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.28) EPS and FY2025 earnings at ($1.22) EPS.

Adial Pharmaceuticals Trading Up 2.9 %

Adial Pharmaceuticals stock opened at $0.74 on Thursday. Adial Pharmaceuticals has a 12 month low of $0.61 and a 12 month high of $3.10. The stock’s 50 day simple moving average is $0.82 and its two-hundred day simple moving average is $0.96. The firm has a market cap of $4.87 million, a PE ratio of -0.22 and a beta of 1.13.

Adial Pharmaceuticals (NASDAQ:ADIL) last issued its earnings results on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.23.

Institutional Investors Weigh In On Adial Pharmaceuticals

Several hedge funds have recently bought and sold shares of ADIL. Geode Capital Management LLC boosted its position in Adial Pharmaceuticals by 36.0% in the 4th quarter. Geode Capital Management LLC now owns 61,847 shares of the company’s stock worth $62,000 after purchasing an additional 16,381 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Adial Pharmaceuticals in the 4th quarter worth approximately $48,000. Finally, Citadel Advisors LLC boosted its position in Adial Pharmaceuticals by 63.8% in the 4th quarter. Citadel Advisors LLC now owns 54,508 shares of the company’s stock worth $55,000 after purchasing an additional 21,238 shares in the last quarter. Hedge funds and other institutional investors own 16.41% of the company’s stock.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.